全文获取类型
收费全文 | 219499篇 |
免费 | 20708篇 |
国内免费 | 15424篇 |
专业分类
耳鼻咽喉 | 1901篇 |
儿科学 | 2192篇 |
妇产科学 | 2979篇 |
基础医学 | 26529篇 |
口腔科学 | 3686篇 |
临床医学 | 30822篇 |
内科学 | 32948篇 |
皮肤病学 | 2226篇 |
神经病学 | 12384篇 |
特种医学 | 8223篇 |
外国民族医学 | 138篇 |
外科学 | 21725篇 |
综合类 | 35427篇 |
现状与发展 | 55篇 |
一般理论 | 19篇 |
预防医学 | 13154篇 |
眼科学 | 6695篇 |
药学 | 22718篇 |
195篇 | |
中国医学 | 12363篇 |
肿瘤学 | 19252篇 |
出版年
2024年 | 696篇 |
2023年 | 3554篇 |
2022年 | 9184篇 |
2021年 | 11516篇 |
2020年 | 8600篇 |
2019年 | 7545篇 |
2018年 | 8036篇 |
2017年 | 7091篇 |
2016年 | 6661篇 |
2015年 | 10256篇 |
2014年 | 12555篇 |
2013年 | 10700篇 |
2012年 | 16010篇 |
2011年 | 17956篇 |
2010年 | 10522篇 |
2009年 | 8185篇 |
2008年 | 11116篇 |
2007年 | 11091篇 |
2006年 | 11230篇 |
2005年 | 11328篇 |
2004年 | 6999篇 |
2003年 | 6613篇 |
2002年 | 5498篇 |
2001年 | 4938篇 |
2000年 | 5347篇 |
1999年 | 5687篇 |
1998年 | 3524篇 |
1997年 | 3497篇 |
1996年 | 2813篇 |
1995年 | 2606篇 |
1994年 | 2142篇 |
1993年 | 1376篇 |
1992年 | 1891篇 |
1991年 | 1595篇 |
1990年 | 1290篇 |
1989年 | 1091篇 |
1988年 | 1014篇 |
1987年 | 890篇 |
1986年 | 726篇 |
1985年 | 525篇 |
1984年 | 336篇 |
1983年 | 242篇 |
1982年 | 149篇 |
1981年 | 145篇 |
1980年 | 111篇 |
1979年 | 142篇 |
1978年 | 49篇 |
1977年 | 53篇 |
1975年 | 57篇 |
1974年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
92.
93.
Xiaoxuan Liu Ameenat L. Solebo Livia Faes Sophie Beese Tasanee Braithwaite Matthew E. Round 《Ocular immunology and inflammation》2020,28(6):898-907
ABSTRACT
Purpose
New instrument-based techniques for anterior chamber (AC) cell counting can offer automation and objectivity above clinician assessment. This review aims to identify such instruments and its correlation with clinician estimates. 相似文献94.
95.
This paper reviews the published literature on a group of developmental disorders of the retina and retinal pigment epithelium which result in focal abnormalities in one or both eyes. They are often asymptomatic, found on routine examination and are generally non-progressive. Some are associated with other systemic abnormalities.Subject terms: Retinal diseases, Eye abnormalities 相似文献
96.
Se-Jin Lee Adam Lehar Yewei Liu Chi Hai Ly Quynh-Mai Pham Michael Michaud Renata Rydzik Daniel W. Youngstrom Michael M. Shen Vesa Kaartinen Emily L. Germain-Lee Thomas A. Rando 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(49):30907
Myostatin (MSTN) is a transforming growth factor-β (TGF-β) family member that normally acts to limit muscle growth. The function of MSTN is partially redundant with that of another TGF-β family member, activin A. MSTN and activin A are capable of signaling through a complex of type II and type I receptors. Here, we investigated the roles of two type II receptors (ACVR2 and ACVR2B) and two type I receptors (ALK4 and ALK5) in the regulation of muscle mass by these ligands by genetically targeting these receptors either alone or in combination specifically in myofibers in mice. We show that targeting signaling in myofibers is sufficient to cause significant increases in muscle mass, showing that myofibers are the direct target for signaling by these ligands in the regulation of muscle growth. Moreover, we show that there is functional redundancy between the two type II receptors as well as between the two type I receptors and that all four type II/type I receptor combinations are utilized in vivo. Targeting signaling specifically in myofibers also led to reductions in overall body fat content and improved glucose metabolism in mice fed either regular chow or a high-fat diet, demonstrating that these metabolic effects are the result of enhanced muscling. We observed no effect, however, on either bone density or muscle regeneration in mice in which signaling was targeted in myofibers. The latter finding implies that MSTN likely signals to other cells, such as satellite cells, in addition to myofibers to regulate muscle homeostasis.Myostatin (MSTN) is a secreted signaling molecule that normally acts to limit skeletal muscle growth (for review, see ref. 1). Mice lacking MSTN exhibit dramatic increases in muscle mass throughout the body, with individual muscles growing to about twice the normal size (2). MSTN appears to play two distinct roles in regulating muscle size, one to regulate the number of muscle fibers that are formed during development and a second to regulate the growth of those fibers postnatally. The sequence of MSTN has been highly conserved through evolution, with the mature MSTN peptide being identical in species as divergent as humans and turkeys (3). The function of MSTN has also been conserved, and targeted or naturally occurring mutations in MSTN have been shown to cause increased muscling in numerous species, including cattle (3–5), sheep (6), dogs (7), rabbits (8), rats (9), swine (10), goats (11), and humans (12). Numerous pharmaceutical and biotechnology companies have developed biologic agents capable of blocking MSTN activity, and these have been tested in clinical trials for a wide range of indications, including Duchenne and facioscapulohumeral muscular dystrophy, inclusion body myositis, muscle atrophy following falls and hip fracture surgery, age-related sarcopenia, Charcot–Marie–Tooth disease, and cachexia due to chronic obstructive pulmonary disease, end-stage kidney disease, and cancer.The finding that certain inhibitors of MSTN signaling can increase muscle mass even in Mstn−/− mice revealed that the function of MSTN as a negative regulator of muscle mass is partially redundant with at least one other TGF-β family member (13, 14), and subsequent studies have identified activin A as one of these cooperating ligands (15, 16). MSTN and activin A share many key regulatory and signaling components. For example, the activities of both MSTN and activin A can be modulated extracellularly by naturally occurring inhibitory binding proteins, including follistatin (17, 18) and the follistatin-related protein, FSTL-3 or FLRG (19, 20). Moreover, MSTN and activin A also appear to share receptor components. Based on in vitro studies, MSTN is capable of binding initially to the activin type II receptors, ACVR2 and ACVR2B (also called ActRIIA and ActRIIB) (18) followed by engagement of the type I receptors, ALK4 and ALK5 (21). In previous studies, we presented genetic evidence supporting a role for both ACVR2 and ACVR2B in mediating MSTN signaling and regulating muscle mass in vivo. Specifically, we showed that mice expressing a truncated, dominant-negative form of ACVR2B in skeletal muscle (18) or carrying deletion mutations in Acvr2 and/or Acvr2b (13) have significantly increased muscle mass. One limitation of the latter study, however, was that we could not examine the consequence of complete loss of both receptors using the deletion alleles, as double homozygous mutants die early during embryogenesis (22). Moreover, the roles that the two type I receptors, ALK4 and ALK5, play in regulating MSTN and activin A signaling in muscle in vivo have not yet been documented using genetic approaches. Here, we present the results of studies in which we used floxed alleles for each of the type II and type I receptor genes in order to target these receptors alone and in combination in muscle fibers. We show that these receptors are functionally redundant and that signaling through each of these receptors contributes to the overall control of muscle mass. 相似文献
97.
98.
99.
100.
S. Xing X. Zhang J. H. Liu X. Huang P. Zhou 《Clinical and experimental immunology》2019,195(1):121-131
Recent experimental strategies to reduce graft-versus-host disease (GVHD) have focused largely on modifying innate immunity. Toll-like receptor (TLR)-driven myeloid differentiation primary response 88 (MyD88)-dependent signalling pathways that initiate adaptive immune function are also critical for the pathogenesis of GVHD. This study aimed to delineate the role of host MyD88 in the development of acute GVHD following fully major histocompatibility complex-mismatched allogeneic bone marrow transplantation (BMT). When myeloablated BALB/c MyD88 knock-out recipients were transplanted with C57BL/6 (B6) donor cells, they developed significantly more severe GVHD than wild-type (WT) BALB/c hosts. The increased morbidity and mortality in MyD88–/– mice correlated with increased serum levels of lipopolysaccharide and elevated inflammatory cytokines in GVHD target organs. Additionally, MyD88 deficiency in BMT recipients led to increased donor T cell expansion and more donor CD11c+ cell intestinal infiltration with apoptotic cells but reduced proliferation of intestinal epithelial cells compared with that in WT BMT recipients. Decreased expression of tight junction mRNA in epithelial cells of MyD88–/– mice suggested that MyD88 contributes to intestinal integrity. Cox-2 expression in the GVHD-targeted organs of WT mice is increased upon GVHD induction, but this enhanced expression was obviously inhibited by MyD88 deficiency. The present findings demonstrate an unexpected role for host MyD88 in preventing GVHD after allogeneic BMT. 相似文献